Related Experiment Videos
Epidermal growth factor receptor in human brain tumors
A Di Carlo1, A Mariano, P E Macchia
1Centro di Endocrinologia ed Oncologia Sperimentale del CNR, II Facoltà di Medicina e Chirurgia, Università di Napoli, Italy.
Journal of Endocrinological Investigation
|January 1, 1992
Summary
Epidermal growth factor receptor (EGF-R) is highly expressed in most human brain tumors, particularly meningiomas and glioblastomas. This finding suggests EGF-R may be a significant target in brain tumor research.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Epidermal growth factor receptor (EGF-R) plays a crucial role in cell growth and proliferation.
- Aberrant EGF-R expression is implicated in various cancers, including brain tumors.
Purpose of the Study:
- To investigate the expression levels of EGF-R in a diverse range of primary human brain tumors and brain metastases.
- To compare EGF-R expression in tumor tissues with histologically normal peritumoral brain tissue.
Main Methods:
- Analysis of EGF-R expression using specific EGF binding assays on plasma membranes from surgically excised human brain tumors and control tissues.
- Western Blot analysis to quantify the total amount of EGF-R protein.
Main Results:
- EGF receptor is expressed at low levels in normal brain tissue.
- High levels of EGF-R were detected in 60% of all intracranial tumors studied.
- Meningiomas (85%) and glioblastomas (71%) showed the highest percentage of EGF-R positivity, while oligodendrogliomas (40%) and astrocytomas (30%) had lower positivity rates.
- A strong correlation was observed between EGF binding capacity and the total EGF-R protein detected by Western Blot.
Conclusions:
- Epidermal growth factor receptor (EGF-R) is significantly overexpressed in a majority of human brain tumors.
- EGF-R expression varies across different histological types of brain tumors, with meningiomas and glioblastomas exhibiting the highest prevalence.
- The findings support the potential of EGF-R as a therapeutic target in specific brain tumor subtypes.